Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell Therapeutics Will Pursue Xyotax Approval For Women With NSCLC

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite having missed the primary endpoints in both STELLAR 3 and 4 trials, Cell Therapeutics plans to seek approval for Xyotax as first-line therapy for women with poor performance status, advanced non-small cell lung cancer.

You may also be interested in...



Novartis And Cell Therapeutics Suspend Xyotax Development

CTI and Novartis are temporarily suspending the PIONEER lung cancer trial to evaluate mortality signals and amend the study protocol.

Novartis And Cell Therapeutics Suspend Xyotax Development

CTI and Novartis are temporarily suspending the PIONEER lung cancer trial to evaluate mortality signals and amend the study protocol.

Novartis Signs Development Deal With Cell Therapeutics For Xyotax

Novartis and CTI will develop and commercialize poliglumex paclitaxel, currently in Phase III for non-small cell lung cancer in women.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel